Intellia Plays Down Concerns About Accidental Germline Transmission in CRISPR Trial

August 21, 2023

(STAT News) – Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing. Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. (Read More)